# A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

> **NCT07260305** · PHASE1 · RECRUITING · sponsor: **Kangabio AUSTRALIA LTD PTY** · enrollment: 57 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** KGX101 injection
- **DRUG:** Envafolimab

## Key facts

- **NCT ID:** NCT07260305
- **Lead sponsor:** Kangabio AUSTRALIA LTD PTY
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-27
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-03-30
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07260305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07260305, "A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07260305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*